Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition

Fig. 3

The gallium compound KP46 widely synergizes with the standard OS chemotherapeutic agent cisplatin. The two compounds were applied either alone or in combination at the indicated concentrations for 72 h continuous drug exposure. Cell viability was determined by an MTT-based survival assay. Dose-response curves at the left are compared to the respective combination indices (CI) calculated by CalcuSyn Software at the right panels. CI < 0.9 represents synergism, >1.1 antagonism and 0.9–1.1 (grey area) additive effects

Back to article page